Navigation Links
Sagent Pharmaceuticals Announces U.S. FDA Approval of Azithromycin for Injection
Date:3/26/2009

- First product approval from Sagent and Strides Arcolab Joint Venture -

SCHAUMBURG, Ill., March 26 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced U.S. Food and Drug Administration (FDA) approval of azithromycin for injection, a semi-synthetic, macrolide antibiotic that is used to treat a wide variety of bacterial infections. Sagent will offer azithromycin in a 500 mg vial for intravenous use. The Company anticipates the launch of azithromycin in April 2009. According to IMS, 2008 sales of azithromycin in the United States approximated $42 million.

"This approval marks an important milestone for Sagent, as azithromycin is the first product from our joint venture - established in 2007 - with Strides Arcolab," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "Strides' manufacturing and development expertise will be invaluable as we move forward with not only azithromycin, one of the world's most widely used antibiotics, but also with the more than 25 products under development by the joint venture."

Under the joint venture agreement, Sagent and Strides Arcolab are developing, supplying and marketing more than 25 injectable products for the U.S. market. Strides is responsible for developing and supplying injectable products that Sagent will market in the United States.

Since late 2007, Sagent launched eight products and currently has more than 70 Abbreviated New Drug Applications (ANDA) submissions on file with the U.S. FDA.

About Azithromycin

Azithromycin for injection is indicated for the treatment of patients with infections caused by susceptible strains of the designated microorganisms in the following conditions: community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Legionella pneumophila'/>"/>

SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Sagent Pharmaceuticals Inc. Completes $53 Million Series A Financing
2. Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
3. Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP
4. Sagent Pharmaceuticals Announces Presentations at Upcoming Lazard Capital Markets and Piper Jaffray Healthcare Conferences
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... the first flu pandemic in the 21st century. The ... than 50 people in the country. Since 2011 the ... seasons). , Infections with influenza pH1N1 virus vary ... has recommended Tamiflu for treatment of patients with severe ... that it targets viral proteins which mutate quickly and ...
(Date:4/23/2014)... donors was safe and effective in treating patients ... difficile , according to a new pilot study ... available online. Known as fecal microbiota transplantation, the ... colonoscope or a nasogastric tube. The findings suggest ... readily available to patients. , A growing concern, ...
(Date:4/23/2014)... Spokane have developed a new way to detect ... the wheel. , Their recently patented technology is ... in drowsy driversand offers an affordable and more ... detection systems. , Van Dongen"Video-based systems that use ... out of its lane are cumbersome and expensive," ...
(Date:4/23/2014)... American Society for Radiation Oncology (ASTRO) has issued ... Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline," ... in the treatment of endometrial cancer. The guideline,s ... issue of Practical Radiation Oncology (PRO), ... full-length guideline is available as an open-access article ...
(Date:4/23/2014)... University researchers have identified an important enzyme pathway that ... too few chromosomes, a condition that has been directly ... associate professor of biochemistry, found that near the end ... enzyme that ensures any breaks in DNA are fully ... genome to daughter cells. This process helps safeguard against ...
Breaking Medicine News(10 mins):Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:WSU innovation improves drowsy driver detection 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2
... , , LA JOLLA, Calif., July ... of TLC(R) Dark Mocha Almond Chewy Granola Bar as the latest ... This new granola bar combines crunchy roasted almonds with rich dark chocolate ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090331/LA91619LOGO ) , , ...
... , NEWARK, Calif., July 21 Novasys Medical, ... urinary incontinence, announced today that it has received $18.95 million in ... financing. The Company received the first tranche of the Series D ... investors ThreeArch Partners and Skyline Ventures. All three participated in the ...
... , , , ... 21 In an unprecedented and historic show of unity, advocates for ... G-8 countries with reneging on their commitments to health by chronically underfunding ... and health systems strengthening across the globe. , ...
... ... design with antibacterial effectiveness. , ... Portland, OR (Vocus) July 21, 2009 -- HemCon Medical Technologies, Inc. ... a next generation, z-folded hemostatic chitosan dressing, designed for battlefield and acute care use ...
... , LAS VEGAS, July 21 ... its subsidiary, Disability Access Corporation (Pink Sheets: DBYC), its wholly ... $245,000 contract with Tuolumne Joint Powers Authority to provide inspection ... exceed $120,000) with the Office of the Independent Monitor for ...
... , , MADISON, N.J., July ... world,s leading provider of diagnostic testing, information and services, announced that ... operations rose to $188 million, or $1.00 per diluted share, from ... of 2008. These results include a previously disclosed benefit associated with ...
Cached Medicine News:Health News:Kashi Company Introduces TLC(R) Dark Mocha Almond Chewy Bar 2Health News:Novasys Medical Receives $18.95 Million in Second Tranche of Series D Financing 2Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 2Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 3Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 4Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 5Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 6Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 7Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 8Health News:Next-Generation Hemostatic Dressing Available for Military Emergencies 2Health News:Next-Generation Hemostatic Dressing Available for Military Emergencies 3Health News:PTS, Inc. Subsidiary Disability Access Corporation Announces $535,000 in New Contracts and Inspection Orders for July 2009 2Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 2Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 3Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 4Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 5Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 6Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 7Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 8Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 9Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 10Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 11Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 12Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 13Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 14
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... January 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... Corporation has announced the release of its next-generation slide scanners, ... of the original series, the NanoZoomer 2.0 converts a 20 ... a 1.9-gigapixel color image in as little as 1 minute ... on a computer monitor, shared across computer networks, used for ...
... , CRANBURY, N.J., Oct. 7 Cornerstone Pharmaceuticals, Inc., ... research scientist Robert A. Weinberg, Ph.D., a founding member ... Professor of Biology at MIT, has joined the company,s ... discoveries of the first human oncogene (the ras ...
Cached Medicine Technology:New 'Virtual Microscope' System from Hamamatsu Offers Faster Acquisition of High-Resolution Slide Scans 2Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board 2Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board 3
The Sedimat 15 Automated sedrate system provides an accurate ESR result in only 15 minutes. Fast, in-office results (before patient leaves the office) can lead to improved patient therapy....
... The Sysmex CA-7000 provides speed ... that is synonymous with Sysmex technology. ... CA-7000 offers throughput of up to ... hour in multi-parameter testing. This ...
... The Sysmex CA-1500 enhances productivity in the ... utilizes three detection methods clotting, chromogenic ... accurate and precise test results every time. ... communication options and random access, the CA-1500 ...
... is the lancing device that has set ... since 1983. This re-usable lancing device assists ... The auto-Lancet is constructed in the USA ... after day, year after year. It's the ...
Medicine Products: